A Phase I Study Of Decitabine (DAC) (IND50733) In Children With Relapsed Or Refractory Acute Leukemia

Trial Profile

A Phase I Study Of Decitabine (DAC) (IND50733) In Children With Relapsed Or Refractory Acute Leukemia

Discontinued
Phase of Trial: Phase I

Latest Information Update: 22 Jan 2013

At a glance

  • Drugs Decitabine (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia
  • Focus Adverse reactions; Biomarker; Pharmacogenomic; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 22 Jan 2013 Actual initiation date changed from Jan 2003 to Dec 2002 as reported by ClinicalTrials.gov.
    • 22 Jan 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 04 Jun 2007 Status changed from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top